Syngene reports Q4 FY25 and full-year FY25 results

Fourth quarter revenue from operations up 11% y-o-y

Full-year revenue from operations up 4%

Syngene wins CDMO Leadership Award 2025

Adjudged winner in the Biologics category by Outsourced Pharma and Life Science Connect publications.

Syngene concludes acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc

New site to increase Syngene’s total single-use bioreactor capacity to 50,000L for large molecules

Read Press Release

Syngene reports Q4 FY25 and full-year FY25 results

Fourth quarter revenue from operations up 11% y-o-y

Full-year revenue from operations up 4%

Read Press Release

Syngene wins CDMO Leadership Award 2025

Adjudged winner in the Biologics category by Outsourced Pharma and Life Science Connect publications.

Syngene concludes acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.

New site to increase Syngene’s total single-use bioreactor capacity to 50,000L for large molecules

Read Press Release

Who we are

We are an innovation-led contract research, development and manufacturing organization offering integrated scientific services from early discovery to commercial supply.

What we do

We offer clients a customized end-to-end solution to fulfil their R&D and manufacturing requirements. Our approach enables us to forge client relationships that move beyond the traditional service outsourcing model into true end-to-end collaborations.

Discovery

Our Discovery Services span the entire spectrum of early stage research from target …

Development

Our Development Services encompass activities from pre-clinical to clinical trials…

Manufacturing

Our Manufacturing services include cGMP-compliant facilities for clinical supplies, registration batches…

Dedicated Centers

Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support…

InstaVisit – Visit Syngene virtually

Syngene InstaVisit is an interactive virtual experience designed to give you a 360 degree view of Syngene’s world-class facilities and capabilities. The platform allows you to change your perspective, look around and zoom in as we take you on a guided tour of Syngene’s labs.

View Now

0 +

Active Clients

Collaborations with top 20 Pharma/Biotech companies

5200

Scientists

Mn sq. ft. of R&D and manufacturing infrastructure

0 +

Patents

Latest News

View all

Syngene Results Q4 FY25 and full-year FY25

Press Release

23rd Apr, 2025

Syngene collaborates with biotech firm to develop bile acid modulator for cholestatic disease treatment

News

22nd Apr, 2025

Antibody-drug conjugates are a significant evolution in drug development landscape: Dr. Kenneth Barr

News

13th Apr, 2025

Insights

View all

Reducing variability in gene expression: Bottlenecks and Solutions

Explore challenges in reducing the variability in gene expression in traditional cell line development (CLD) and the power of the transposon system to address these inefficiencies.

23 January 2025

Quantifying a biomarker in mice brain for treating mood and anxiety disorders

A robust LC-MS-based quantitative method developed at Syngene to measure biomarker 2-AG in mice brain tissues for treating mood and anxiety disorders.

18 October 2024

Risk assessment strategy for nitrosamine drug substance-related impurities

The potential causes of nitrosamine drug substance-related impurities and Syngene’s strategic framework for identification and management of these impurities to meet regulatory guidelines for product safety.

2 September 2024

Upcoming events

View all

AACR 2025

April 25th-30th

Chicago

International Conference on Biologics & Biosimilars Italy (Keynoteconnect)

April 28th

Rome

AAPS – NBC 2025

May 4th-7th

Boston

Swiss Biotech Day 2025

May 5th-6th

Basel

Meet2Win 2025

May 6th-7th

Bordeaux

BIO Korea 2025

May 7th-9th

Seoul

Corporate Social Responsibility

To strive towards developing and sustaining healthy and empowered communities by improving the quality of life.

Governance

Behind consistent growth is good governance

Careers

Discover a world of opportunities

Annual Reports

Touching a billon lives through innnovation

Discovery

Development

Manufacturing

Discovery

Development & Manufacturing

SynVent Integrated Drug Discovery

Emerging Biopharma

Dedicated Centers

Center for Advanced Protein Studies (CAPS)

Who we are

What we do

Discovery

Development

Manufacturing

Dedicated Centers

InstaVisit – Visit Syngene virtually

Latest News

Syngene Results Q4 FY25 and full-year FY25

Syngene collaborates with biotech firm to develop bile acid modulator for cholestatic disease treatment

Antibody-drug conjugates are a significant evolution in drug development landscape: Dr. Kenneth Barr

Insights

Reducing variability in gene expression: Bottlenecks and Solutions

Quantifying a biomarker in mice brain for treating mood and anxiety disorders

Risk assessment strategy for nitrosamine drug substance-related impurities

Upcoming events

Corporate Social Responsibility

Governance

Careers

Annual Reports

Sign-up for our newsletter

Quick links

Business

Get in touch

Other links

To view or email, Please share your details view

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details